Search API

0 min read

New data collected by The Vaccine Confidence Project at the London School of Hygiene & Tropical Medicine and published today by UNICEF indicates a decrease in vaccine confidence in most countries.

As of April 20, 2023, people under 35 and women were more likely to report less confidence about vaccines for children after the start of the pandemic.

However, China, India, and Mexico were the only countries studied where the data suggests the perception of the importance of vaccines held firm or even improved.

In a related press release, Catherine Russell, UNICEF Executive Director, commented, "This data is a worrying warning signal. We cannot allow confidence in routine immunizations to become another victim of the pandemic."

"Otherwise, the next wave of deaths could be of more children with measles, diphtheria, or other preventable diseases."

Launched in 2015, the Vaccine Confidence Index™ (VCI) is a digital tool for gaining data-led insights into vaccine confidence at global, regional, and national levels.

In addition to measuring overall trust in vaccines, the VCI guides where to prioritize confidence building.

Data presented in this report comes from a large-scale retrospective study of changes in vaccine confidence between 2015 and November 2019 and since 2021. 

Vaccine Treats: 
COVID-19
Image: 
Image Caption: 
World VCI map April 20, 2023
Live Blog Update Author: 
Karen McClorey Hackett
Location Tags: 
Worldwide
0 min read

According to recent data from the Republic of Costa Rica Health Surveillance Directorate of the Ministry of Health, a total of 105 positive cases of malaria have been identified in the Huerta Caribe region.

And 2,844 people treated from the communities of Finca 12, PCC, Medio Queso, Coquital, and San Gerardo, in the canton of Los Chiles, chose to prevent the spread of malaria, and 726 homes have been visited in which a total of 9,136 doses of chloroquine have been provided.

Most people detected as of April 13, 2023, were between 20 to 39 years of age.

It is essential to highlight that the Ministry of Health's goal is eliminating malaria by 2025.

To notify international travelers, the U.S. Centers for Disease Control and Prevention (CDC) issued an Alert - Level 2, Practice Enhanced Precautions on April 17, 2023, regarding Costa Rica's malaria outbreak.

The CDC warned malaria is a medical emergency, and appropriate treatment should not be delayed. And seek medical care if you develop fever, chills, sweats, headache, vomiting, or body aches. 

According to the World Health Organization Malaria Report released in December 2022, there were an estimated 619,000 malaria-related fatalities globally in 2021, with 568,000 deaths.

Additionally, the CDC stated if you are traveling to Limón or Alajuela Province, you should speak to your healthcare professional about how to prevent mosquito bites and which antimalarial drug is best.

Furthermore, as a prevention, you could take antimalarial drugs before travel. 

According to the CDC, malaria is a vaccine-preventable mosquito-borne disease. 

Vaccines such as RTS,S, and R21 have been approved in various countries and are reported to be effective at preventing disease.

Unfortunately, the U.S. Food and Drug Administration had not approved a malaria vaccine as of April 19, 2023.

This article was updated on April 20, 2023, with local links.

Vaccine Treats: 
Malaria
Image: 
Image Caption: 
U.S. CDC Map of malaria outbreak in Costa Rica April 2023
Live Blog Update Author: 
Karen McClorey Hackett
Location Tags: 
Costa Rica
Vaccine: 
Mosquirix Malaria Vaccine
0 min read

The journal ScienceDirect recently published a study on vaccine-derived poliovirus serotype 2 outbreaks and response in the Democratic Republic of the Congo (DRC) 2017–2021.

Published on April 6, 2023, this study revealed previous VDPV serotype 2 outbreaks (cVDPV2) documented outbreaks in the DRC since 2005.

The nine cVDPV2 outbreaks detected during 2005–2012 resulted in 73 paralysis cases.

And from January 2017–December 31, 2021, 19 cVDPV2 outbreaks were detected in DRC, resulting in 235 paralysis cases in 18 of DRC's 26 provinces.

Moreover, the DRC-KAS-3 cVDPV2 outbreak that circulated during 2019–2021 resulted in 101 paralysis cases in 10 provinces and was the largest recorded in DRC.

To notify visitors to the DRC, the U.S. Centers for Disease Control and Prevention (CDC) reissued a Global Polio Alert - Level 2, Practice Enhanced Precautions on March 22, 2023.

This CDC Travel Alert included the DRC.

Before traveling to any destination listed, the CDC suggests that adults who previously completed the entire polio vaccine series receive a single, lifetime booster dose of the polio vaccine.

In the U.S., various polio vaccines are available at health clinics and pharmacies, such as United and Market Street in Lubbock, Texas.

Vaccine Treats: 
Polio
Image: 
Image Caption: 
U.S. CDC polio outbreak alert March 2023
Live Blog Update Author: 
Karen McClorey Hackett
Location Tags: 
Kinshasa
Vaccine: 
nOPV2 Polio Vaccine March 2023
0 min read

The U.S. CDC's Advisory Committee on Immunization Practices (ACIP) conducted a digital meeting today led by Dr. Grace Lee focused on the U.S. FDA's updated COVID-19 vaccine emergency use authorizations (EUAs).

The EUAs were structured by the FDA on April 18, 2023, to simplify the use of bivalent mRNA vaccines for all doses and indications administered to individuals ages six months and older and additional mRNA dose(s) for specific populations.

These changes did not impact the Novavax protein-based COVID-19 vaccine (Nuvaxovid™, CovoVax™).

The ACIP also reviewed the following presentations on April 19, 2023:

  • Vaccine safety updates,
  • Vaccine effectiveness data updates,
  • Epidemiology and hospitalization data,
  • Benefit-risk analysis,
  • Considerations for transition to bivalent primary series,
  • Future directions of COVID-19 vaccines, including updates to vaccine policy.

Both the CDC and FDA staff confirmed today that a meeting in June 2023 would offer additional clarity before any Fall 2023 COVID-19 vaccination program,

Vaccine Treats: 
COVID-19
Image: 
Image Caption: 
U.S. CDC April 19, 2023
Live Blog Update Author: 
Don Hackett
Location Tags: 
Atlanta
Vaccine: 
Novavax COVID-19 Vaccine

Vaxcyte Pneumococcal Vaccines

Vaxcyte Pneumococcal Vaccines Clinical Trials, Indication, Side Effects

Vaxcyte Inc.'s carrier-sparing Pneumococcal Vaccine (PCV) franchise candidates, VAX-24, a 24-valent PCV, and VAX-31, a 31-valent PCV, are being studied for the prevention of invasive pneumococcal disease (IPD). Both VAX-24 and VAX-31 are designed to improve upon the standard-of-care PCVs for children and adults by covering the serotypes responsible for a significant portion of IPD in circulation and are associated with high case-fatality rates, antibiotic resistance, and meningitis while maintaining coverage of previously circulating strains that are currently contained through continued vaccination practice.

Vaxcyte is re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF™ cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company's system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficient create and deliver high-fidelity vaccines with enhanced immunological benefits disease (PD) is an infection caused by Streptococcus pneumonia  (pneumococcus) bacteria. It can result in IPD, including meningitis and bacteremia, and non-invasive PD, including pneumonia, otitis media, and sinusitis. 

Grant Pickering, CEO and Co-founder of Vaxcyte, commented in a press release on November 6, 2024: "We believe the recent topline results for VAX-31 in adults demonstrate its potential as a best-in-class PCV to provide protection against both currently circulating and historically prevalent strains while setting a new standard for immunogenicity. In addition, we plan to initiate the VAX-31 infant Phase 2 study in the first quarter of 2025, subject to IND application clearance by the end of this year."

Vaxcyte (Nasdaq: PCVX) is a vaccine innovation company that engineers high-fidelity vaccines to protect humans from the consequences of bacterial diseases. On September 4, 2024, Vaxcyte announced that it had commenced an underwritten public offering of $1.4 billion of its common stock and pre-funded warrants.

VAX-24 Vaccine

VAX-24 is an investigational 24-valent PCV candidate designed to prevent IPD, which can be most serious for infants, young children, older adults, and those with immune deficiencies or certain chronic health conditions. In July 2024, the VAX-24 Phase 2 study results in adults aged 65 and older were published in the journal Vaccine. The study evaluated the safety, tolerability, and immunogenicity of Vaxcyte's investigational 24-valent, carrier-sparing PCV compared to Prevnar 20® (PCV20) for preventing invasive pneumococcal disease (IPD) in healthy adults. The results showed that VAX-24 demonstrated a safety and tolerability profile comparable to PCV20 across all ages and doses studied. The VAX-24 2.2mcg dose showed an overall improvement in immune responses compared to PCV20 relative to the prior Phase 2 study results in adults aged 50-64. The U.S. FDA awarded VAX-24 Breakthrough Therapy Designation on January 5, 2023, and cleared the Company's infant Investigational New Drug application for VAX-24 on February 21, 2023. 

VAX-31 Vaccine

VAX-31 is a next-generation PVC vaccine and is the broadest-spectrum PCV candidate in the clinic today. As of February 5, 2025, Vaxcyte announced that the first study participants had been dosed in the second and final stage of the ongoing Phase 2 study of VAX-31 in healthy infants. Advancement to Stage 2 follows a blinded assessment of the Stage 1 safety and tolerability data per the study protocol. The Company expects to share topline data from the primary three-dose immunization series of the study in mid-2026, followed by topline data from the booster dose approximately nine months later.

Vaxcyte Inc. Vaccine News

February 5, 2025 - “Advancing to Stage 2 of the VAX-31 infant Phase 2 study represents a significant step forward in evaluating the broadest vaccine candidate in the clinic today for this vulnerable population,” said Grant Pickering, Chief Executive Officer and Co-Founder of Vaxcyte.

December 3, 2024 - “The initiation of the VAX-31 Phase 2 infant study marks a significant milestone as we continue advancing our PCV clinical programs, which also include the fully enrolled, ongoing VAX-24 Phase 2 infant study,” said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte.

September 3, 2024 - The Company presented topline results from the Phase 1/2 study evaluating the safety, tolerability, and immunogenicity of VAX-31 in healthy adults aged 50 and older.

August 6, 2024 - The Company announced it had cash, cash equivalents, and investments of $1,851.9 million as of June 30, 2024, compared to $1,242.9 million as of December 31, 2023.

January 4, 2024 - Mr. Grant Pickering commented in a press release, "We also received encouraging feedback from the FDA regarding the licensure requirements for VAX-24 in adults. We are fortunate to be afforded these ongoing discussions, given the Breakthrough Therapy designation granted to VAX-24, and expect to seek additional CMC-focused input from regulators as we prepare for and conduct the adult Phase 3 program, which will comprise several studies. With VAX-24 and VAX-31, we are confident in our plans to build a best-in-class PCV franchise that delivers the broadest spectrum of coverage against invasive pneumococcal disease."

July 11, 2023 - Vaxcyte, Inc. announced that the ongoing Phase 2 study of VAX-24 in healthy infants is advancing to the second and final stage of the study. 

Vaxcyte Vaccine Clinical Trials

VAX-24 Infant Phase 2 Study - The VAX-24 infant Phase 2 clinical study, which is now fully enrolled with 802 healthy infants, is a randomized, observer-blind, dose-finding two-stage clinical study evaluating the safety, tolerability, and immunogenicity of VAX-24. The Stage 1 portion of the study evaluated the safety and tolerability of a single injection of VAX-24 at three dose levels (low dose/1.1mcg, middle dose/2.2mcg, mixed dose/2.2mcg or 4.4mcg) and compared to VAXNEUVANCE™ (PCV15), which was the broadest-spectrum PCV at the time of study initiation, in 48 infants. The Stage 2 portion evaluates the safety, tolerability, and immunogenicity of VAX-24 at the same three dose levels and compared to Prevnar 20® (PCV20), currently the broadest-spectrum PCV recommended by the Advisory Committee on Immunization Practices (ACIP), in 754 infants. Participants who received VAX-24 in Stage 1 will continue the standard dosing regimen as part of Stage 2 and will be included in the study's safety, tolerability, and immunogenicity analysis.

0 min read
Manufacturer: 
Vaxcyte, Inc
Reviewer: 
Robert Carlson, MD
Vaccine: 
Vaxcyte Pneumococcal Vaccines
VIS: 
PDF
Availability: 
N/A
Generic: 
VAX-24, VAX-31
Drug Class: 
Vaccine
Clinical Trial Phase I: 
Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults
Clinical Trial Phase II: 
Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults
Condition: 
Pneumococcal
Last Reviewed: 
Friday, February 21, 2025 - 07:30
Status: 
Candidate
Manufacturer Country ID: 
US
FDA First In Class: 
Yes
0 min read

The journal Nature recently published a news article focused on an innovative tactic to reduce the number of dengue cases in Brazil.

This program aims to protect up to 70 million Brazilians from diseases such as dengue.

The non-profit World Mosquito Program announced it would release about five billion bacteria-infected mosquitoes annually in many of Brazil’s urban areas over the next ten years.

Researchers have tested the release of this type of mosquito, which carries a Wolbachia bacterium that stops mosquitoes from transmitting viruses. Wolbachia naturally infects about half of all insect species.

In Brazil, previous test results have been modest. For example, in Niterói, the intervention was associated with a 69% decrease in dengue cases, while in Rio de Janeiro, the reduction was 38%.

But this will be the first time that the technology is dispersed nationwide.

Nature posts the unedited article as of April 14, 2023.

In the U.S., the state of Florida launched a similar program in May 2021.

Florida continues to report the most travel-related and locally acquired dengue cases in the U.S. during 2023.

Globally, two dengue vaccines have been authorized.

Vaccine Treats: 
Dengue
Image: 
Image Caption: 
by Gabriela Piwowarska
Live Blog Update Author: 
Karen McClorey Hackett
Location Tags: 
Brazil
Vaccine: 
QDENGA (TAK-003) Dengue Vaccine
0 min read

The Nigeria Centre for Disease Control and Prevention (NCDC) has reported an unprecedented negative trend in confirmed cases of Lassa Fever.

The NCDC recently confirmed a total of 869 confirmed Lassa Fever cases and 151 related fatalities from 26 states and 101 local government areas.

Cumulatively for 2023, the case fatality rate (CFR) of 17.4%.

As of April 9, 2023, for week #14 , the number of new confirmed cases is 23 from Bauchi, Ondo, Edo, Taraba, Lagos, and Enugu Niergian States.

Lassa fever is an acute viral hemorrhagic fever with a natural reservoir in the Mastomys natalensis rodent (African rat).

As of early March 2023, the U.S. CDC's Watch - Level 1, Practice Usual Precautions notice alerts visitors to Nirgeria of the health risk.

As of April 19, 2023, the U.S. FDA had not approved a Lassa fever vaccine.

Vaccine Treats: 
Lassa Fever
Image: 
Image Caption: 
U.S. CDC Nigeria Lassa fever Travel Notice March 2023
Live Blog Update Author: 
Karen McClorey Hackett
Location Tags: 
Lagos
Vaccine: 
INO-4500 Lassa Fever Vaccine
Dengue outbreaks April 2023

Dengue Travel Alert for the Americas Reissued

Dengue vaccines are authorized in various countries
April 19, 2023
0 min read

AstraZeneca recently highlighted new data at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), reinforcing its ambition to provide long-lasting immunity for millions globally. 

For example, data featuring AZD3152, AstraZeneca’s investigational long-acting COVID-19 antibody, shows the investigational COVID-19 long-acting antibody neutralizes all known variants of concern identified to date.

Iskra Reic, Executive Vice President, Vaccines and Immune Therapies, AstraZeneca, stated in a press release on April 14, 2023, “Our first in vitro data from our next generation long-acting antibody, AZD3152, shows its potential to protect the immunocompromised from all known COVID-19 variants of concern to date.”

Last updated on April 3, 2023, the aim of the phase I/III clinical study is to evaluate the safety and neutralizing activity of AZD3152 compared with AZD7442 for pre-exposure prophylaxis of COVID-19 and separately evaluate the safety and PK of AZD5156, a combination of AZD3152 and AZD1061.

Other COVID-19 antibody news is posted by CoronavirusToday.com.

Vaccine Treats: 
COVID-19
Image: 
Image Caption: 
by Bruno G.
Live Blog Update Author: 
Don Hackett
Location Tags: 
London
Vaccine: 
EvuSheld Long-Acting Antibody 2023
0 min read

According to the U.S. government, pharmacies are the leading distribution outlet for COVID-19 vaccines. During the 2022-2023 season, available data show that more than two-thirds of adult COVID-19 vaccinations were administered at pharmacies.

Announced on April 18, 2023, the U.S. Department of Health & Human Services (HHS) announced the ‘HHS Bridge Access Program For COVID-19 Vaccines and Treatments Program (“Program”) to maintain broad access to COVID-19 vaccines for millions of uninsured Americans.

The program will create a unique $1.1 billion public-private partnership to help maintain uninsured individuals’ access to COVID-19 care at local pharmacies.

HHS wrote pharmacies had been a critical partner in the Administration’s response to COVID-19 and a vital access point for millions of Americans in receiving convenient and timely COVID-19 vaccines, treatments, and tests.

In the future, HHS aims to ensure that the pharmacy setting remains a place of access for the uninsured.

In building the Program, CDC will establish contracts with pharmacies to enable them to continue offering COVID-19 vaccines and designated treatments with no out-of-pocket costs to uninsured individuals, maintaining this critical access point for this population.

And pharmacies will also be expected to conduct outreach regarding the availability of the COVID-19 vaccine, including through community partnerships focusing on underserved populations. 

Together, these efforts will create a unique public-private partnership that will help maintain uninsured individuals’ access to COVID-19 care at their local pharmacies, local health centers, and public health infrastructure. 

Vaccine Treats: 
COVID-19
Image: 
Image Caption: 
U.S. HHS Secretary Becerra April 2023
Live Blog Update Author: 
Don Hackett
Location Tags: 
Washington DC
Vaccine: 
Novavax COVID-19 Vaccine